Elaine Ullian, Director at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 20,000 shares at $127.62 ($2.5M) on 2015-11-02, disclosed to the SEC on 2015-11-04.
Scheduled sale ($2.5M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $123.66 | 900 | $111K | 4.4% |
| 2 | $125.09 | 700 | $88K | 3.5% |
| 3 | $125.98 | 9,592 | $1.2M | 47.8% |
| 4 | $126.91 | 6,708 | $851K | 33.7% |
| 5 | $127.62 | 2,100 | $268K | 10.6% |
| Total | $126.33 avg | 20,000 |
| $2.5M |
| 100% |
| Filing → |
| HOLX | SELL | 2017-07-06 | $801K | — | Filing → |
| HOLX | SELL | 2017-06-06 | $786K | — | Filing → |
| HOLX | SELL | 2017-05-05 | $799K | — | Filing → |